\nDr. S\u00fcalp Tansan: Significant progress has been made in two main areas. Firstly, adjuvant therapy, that is, treatments given after surgery to prevent the disease from recurring \u2013 as a kind of insurance \u2013 has had revolutionary positive results in oncology. The benefits of adjuvant therapies have been redefined in lung, breast, and colon cancers. The second important development was the demonstration in targeted therapies that multiple targeted drugs can positively alter the course of very important diseases.<\/p>\n
ailem.com: What is the role of trastuzumab (Herceptin) in early-stage breast cancer?<\/strong> ailem.com: What are the other important developments in breast cancer?<\/strong> ailem.com: 2. What is the role of chemotherapy in early-stage lung cancer?<\/strong> ailem.com: Are there any other important developments in lung cancer?<\/strong> ailem.com: What is the role of the drug Oxaliplatin in colon cancer?<\/strong> ailem.com: What are the other important developments in colon cancer?<\/strong> Apart from these, there are small but significant advancements in many diseases. It seems that with the increase in the number and types of targeted therapies, a new era is dawning in cancer treatment. Hopefully, in the coming days, we will have many more new and effective treatments, and thanks to these, our cancer patients will have a better chance of living longer and healthier lives, and of recovering.<\/p>\n Ailem.com \/ 06.05.2006<\/strong><\/p>","protected":false},"excerpt":{"rendered":" We continue our conversation with Dr. S\u00fcalp Tansan, one of the leading oncologists in T\u00fcrkiye, who answers your questions, our members, on cancer treatments in adults. ailem.com: What kind of developments have taken place in cancer treatments, especially in the last year? Dr. S\u00fcalp Tansan: Significant developments have taken place in two main areas. Firstly, adjuvant therapy, that is, to prevent the disease from returning after surgery \u2013 as a kind of insurance \u2013<\/p>","protected":false},"author":3,"featured_media":2818,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[523],"tags":[],"class_list":["post-2817","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-basinda-tansan"],"yoast_head":"\n
\nDr. S\u00fcalp Tansan: Trastuzumab daha \u00f6nceki yaz\u0131lar\u0131mda bahsetti\u011fim gibi meme kanseri h\u00fccreleri \u00fcst\u00fcnde bulunan her-2 (c-erb B2) onkojenine ba\u011flanan bir monoklonal antikor. Bu onkojen t\u00fcm meme kanseri vakalar\u0131n\u0131n %30\u2019unda bulunan bir nevi beslenme a\u011f\u0131zc\u0131\u011f\u0131. Patoloji\u2019de meme kanseri bloklar\u0131 \u00fcst\u00fcnde immun boyama veya FISH y\u00f6ntemi ile varl\u0131\u011f\u0131 belirleniyor. Her-2 pozitif olan kanserler genellikle daha agresif olan, metastaz kapasitesi y\u00fcksek ve standart kemoterapiye diren\u00e7li olabilen t\u00fcm\u00f6rler. Trastuzumab gerek tek ba\u015f\u0131na gerekse kemoterapi ile beraber bu t\u00fcm\u00f6rlerde ola\u011fan\u00fcst\u00fc etki g\u00f6sterebiliyor. Zaten bu y\u00fczden son bir iki senede metastatik olup her-2 pozitif olan t\u00fcm\u00f6rlerde, trastuzumab tedavinin vazge\u00e7ilmez bir par\u00e7as\u0131 haline gelmi\u015fti. Son bir y\u0131lda iki \u00f6nemli ve b\u00fcy\u00fck ara\u015ft\u0131rma trastuzumab\u2019\u0131n erken evre (her-2 pozitif) meme kanserlerinde kemoterapiye eklendi\u011finde sadece kemoterapi alan hastalara k\u0131yasla kanserin geri gelme riskini yar\u0131 yar\u0131ya azaltt\u0131\u011f\u0131 ortaya \u00e7\u0131kt\u0131 !! Bu nedenle art\u0131k her-2 pozitif ve y\u00fcksek risk (lenf bezi pozitif veya lenf bezi negative olup olumsuz \u00f6zellikleri olan) meme kanserlerinde adjuvant tedavinin vazge\u00e7ilmez bir par\u00e7as\u0131 haline geldi. Tek problem, trastuzumab alan hastalarda %3 oran\u0131nda artm\u0131\u015f bir kalp yetmezli\u011fi riski olmas\u0131 (ki bu da genellikle ya\u015fl\u0131 kalp hastas\u0131 veya kontrolsuz hipertansiyonu olan hastalarda g\u00f6r\u00fcl\u00fcyor). Bundan sonra meme kanserinde ameliyat olan her hastada \u00f6strojen ve progesterone resept\u00f6r tayinine ek olarak t\u00fcm\u00f6rde mutlaka her-2 durumunun belirlenmesi en ba\u015ftan gerekli olacak. Tedavi bi\u00e7imine de buna g\u00f6re karar verilmeli ve tercihen en yak\u0131n zamanda \u00fclkemizde erken ever meme kanseri tedavisinde trastuzumab\u2019\u0131n yarar\u0131n tan\u0131n\u0131p ilac\u0131n bu endikasyon i\u00e7in de sa\u011flanmas\u0131n\u0131n yollar\u0131n\u0131n bulunmas\u0131 gerekti\u011fini d\u00fc\u015f\u00fcn\u00fcyorum (\u015eu anda sadece metastatik hastalar i\u00e7in devlet trastuzumab sa\u011fl\u0131yor).<\/p>\n
\n![\"\"](\"https:\/\/tansan.com.tr\/wp-content\/uploads\/2020\/03\/cancerm1.jpg\")
Dr. S\u00fcalp Tansan: \u00b7 Beslenmede ya\u011f oran\u0131n\u0131n d\u00fc\u015f\u00fcr\u00fclmesi ve d\u00fczenli egzersiz \u2013 her ikisi de ba\u011f\u0131ms\u0131z olarak, erken ever meme kanserinde hastal\u0131\u011f\u0131n geri gelme riskini %25-50 oran\u0131nda d\u00fc\u015f\u00fcrebiliyor
\n\u2022 Aromatase inhibitors reduce the risk of disease recurrence in early-stage breast cancer more than tamoxifen.
\n\u2022 In women under 50, digital mammography can detect breast cancer more accurately than standard mammography.<\/p>\n
\nDr. S\u00fcalp Tansan: Senelerdir kemoterapinin erken ever akci\u011fer kanserinde yararl\u0131 bir rol\u00fc g\u00f6sterilememi\u015fti. Erken Evre akci\u011fer kanserleri daha \u00f6nce de bahsetti\u011fim gibi geri gelme riski y\u00fcksek olan kanserler. Son bir senede sonu\u00e7lar\u0131 a\u00e7\u0131klanan \u00e7ok \u00f6nemlive b\u00fcy\u00fck bir ara\u015ft\u0131rma erken ever akci\u011fer kanserlerinde adjuvant kemoterapinin ameliyat sonras\u0131 hastal\u0131\u011f\u0131n geri gelme riskini %40 azaltt\u0131\u011f\u0131 g\u00f6sterildi ki bu geri gelme riski y\u00fcksek olan bu hastal\u0131kta devrim \u00f6zelli\u011fi ta\u015f\u0131yan bir sonu\u00e7 olarak alg\u0131lanmal\u0131. Bu da demek ki akci\u011fer kanseri te\u015fhisi olan her hasta mutlaka Medikal Onkoloji uzman\u0131na dan\u0131\u015fmal\u0131 ve kemoterapiden yarar g\u00f6r\u00fcp g\u00f6remeyece\u011fini \u00f6\u011frenmeli.<\/p>\n
\nDr. S\u00fcalp Tansan: \u2022 In metastatic lung cancer, Bevacizumab-Avastin (a monoclonal antibody that prevents vasodilation) can significantly prolong survival when added to chemotherapy. This drug can be used in all types of metastatic lung cancer (non-small cell lung cancer) except epidermoid cancer (which means two-thirds of all patients). Bevacizumab (Avastin) is expected to be available in T\u00fcrkiye by the end of February 2006.<\/p>\n
\nDr. S\u00fcalp Tansan: Oxaliplatin kanser tedavisinde kullan\u0131lan \u00fc\u00e7\u00fcnc\u00fc jenerasyon platin grubu bir ila\u00e7. Daha once yap\u0131lan \u00e7al\u0131\u015fmalarda oxaliplatinin standart kemoterapiye eklenmesinin hastalar\u0131n \u00f6mr\u00fcn\u00fc uzatt\u0131\u011f\u0131 ve tedavinin ba\u015far\u0131 \u015fans\u0131n\u0131 artt\u0131rd\u0131\u011f\u0131 g\u00f6sterildi. Son y\u0131lda iki \u00f6nemli \u00e7al\u0131\u015fma erken evre kolon kanserinde (Evre II-III) oxaliplatin\u2019in kemoterapiye eklenmesinin (FOLFOX tedavisi) kanserin geri gelme riskini %21-24 oran\u0131nda azaltt\u0131\u011f\u0131n\u0131 g\u00f6sterdi. Bu da demek ki kolon kanserinden ameliyat olan her hasta doktoruna ameliyat sonras\u0131 oxaliplatin i\u00e7eren bir tedaviden yarar g\u00f6r\u00fcp g\u00f6rmeyece\u011fini sormal\u0131.<\/p>\n
\nDr. S\u00fcalp Tansan: \u2022 In metastatic colon cancer, adding Bevacizumab (Avastin) to chemotherapy significantly increases the patient's lifespan and likelihood of responding to treatment compared to those receiving chemotherapy alone. All patients undergoing treatment for metastatic colon cancer should definitely consult their doctor about whether they would benefit from Bevacizumab treatment.<\/p>\n